Loading…
Cilengitide restrains the osteoclast‐like bone resorbing activity of myeloma plasma cells
Summary Cilengitide (CLG) is an inhibitor of both αvβ3 and αvβ5 integrins, with a defined anti‐tumour effect in glioblastoma. Pre‐clinical studies demonstrate its ability to restrain the bone resorbing property of metastatic osteotropic tumours and we have previously shown that the disablement of αv...
Saved in:
Published in: | British journal of haematology 2016-04, Vol.173 (1), p.59-69 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03 |
---|---|
cites | cdi_FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03 |
container_end_page | 69 |
container_issue | 1 |
container_start_page | 59 |
container_title | British journal of haematology |
container_volume | 173 |
creator | Tucci, Marco Stucci, Stefania Felici, Claudia Cafforio, Paola Resta, Leonardo Rossi, Roberta Silvestris, Franco |
description | Summary
Cilengitide (CLG) is an inhibitor of both αvβ3 and αvβ5 integrins, with a defined anti‐tumour effect in glioblastoma. Pre‐clinical studies demonstrate its ability to restrain the bone resorbing property of metastatic osteotropic tumours and we have previously shown that the disablement of αvβ3 in multiple myeloma (MM) plasma cells results in exhaustion of their in vitro osteoclast (OC)‐like activity on bone substrate. Here, we investigated the effect of CLG on this functional property of MM cells. Both αvβ3 and αvβ5 were measured on primary marrow MM cells from 19 patients, and the effect of CLG on proliferation, apoptosis and adhesion was investigated in parallel with MM cell lines and OCs from healthy donors. In addition, the effect of CLG on the capability of malignant plasma cells to produce erosive lacunae on calcium phosphate was explored in relation to the activation of intracellular kinases of molecular pathways of both integrins. Ultrastructural microscopy was used to evaluate the morphological changes in MM cells due to the effect of CLG on cell adhesion. The data from our study demonstrate that CLG restrains the bone resorbing function of MM cells by disabling their adhesion properties. Further investigations in pre‐clinical studies of osteotropic tumours are warranted. |
doi_str_mv | 10.1111/bjh.13922 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1785242769</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1785242769</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03</originalsourceid><addsrcrecordid>eNqNkL1OwzAURi0EoqUw8AIoIwxp_RM78QgVUFAlFpgYItu1W5ckLnEKysYj8Iw8CW5T2JC4w_2Wo0_3HgBOERyiMCO5XAwR4RjvgT4ijMYYJWgf9CGEaYxgkvXAkfdLCBGBFB2CHmYpzjjjffA8toWu5raxMx3V2je1sJWPmoWOnG-0U4XwzdfHZ2FfdCRdtYVcLW01j4Rq7Jtt2siZqGx14UoRrQIfQumi8MfgwIjC65NdDsDTzfXjeBJPH27vxpfTWCWU45gqSgQlqeZcKoLDkuEZLqmAhEFIM2VMlmAulNEEZ4akwkiMoJEsSVIJyQCcd72r2r2uww95af3mAlFpt_Y5SjOKE5wy_g80ZQzzDJKAXnSoqp33tTb5qralqNscwXyjPQ_a8632wJ7tatey1LNf8sdzAEYd8B50t3835Vf3k67yG9NkjVQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1776629803</pqid></control><display><type>article</type><title>Cilengitide restrains the osteoclast‐like bone resorbing activity of myeloma plasma cells</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Tucci, Marco ; Stucci, Stefania ; Felici, Claudia ; Cafforio, Paola ; Resta, Leonardo ; Rossi, Roberta ; Silvestris, Franco</creator><creatorcontrib>Tucci, Marco ; Stucci, Stefania ; Felici, Claudia ; Cafforio, Paola ; Resta, Leonardo ; Rossi, Roberta ; Silvestris, Franco</creatorcontrib><description>Summary
Cilengitide (CLG) is an inhibitor of both αvβ3 and αvβ5 integrins, with a defined anti‐tumour effect in glioblastoma. Pre‐clinical studies demonstrate its ability to restrain the bone resorbing property of metastatic osteotropic tumours and we have previously shown that the disablement of αvβ3 in multiple myeloma (MM) plasma cells results in exhaustion of their in vitro osteoclast (OC)‐like activity on bone substrate. Here, we investigated the effect of CLG on this functional property of MM cells. Both αvβ3 and αvβ5 were measured on primary marrow MM cells from 19 patients, and the effect of CLG on proliferation, apoptosis and adhesion was investigated in parallel with MM cell lines and OCs from healthy donors. In addition, the effect of CLG on the capability of malignant plasma cells to produce erosive lacunae on calcium phosphate was explored in relation to the activation of intracellular kinases of molecular pathways of both integrins. Ultrastructural microscopy was used to evaluate the morphological changes in MM cells due to the effect of CLG on cell adhesion. The data from our study demonstrate that CLG restrains the bone resorbing function of MM cells by disabling their adhesion properties. Further investigations in pre‐clinical studies of osteotropic tumours are warranted.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.13922</identifier><identifier>PMID: 26728969</identifier><language>eng</language><publisher>England</publisher><subject>Apoptosis - drug effects ; bone disease ; Bone Resorption - metabolism ; Bone Resorption - pathology ; Cell Adhesion - drug effects ; Cell Proliferation - drug effects ; cilengitide ; Female ; Humans ; Integrin alphaVbeta3 - metabolism ; Male ; multiple myeloma ; Multiple Myeloma - metabolism ; Multiple Myeloma - pathology ; Neoplasm Proteins - metabolism ; osteoclasts ; Osteoclasts - metabolism ; Osteoclasts - pathology ; Plasma Cells - metabolism ; Plasma Cells - pathology ; Receptors, Vitronectin - metabolism ; Snake Venoms - pharmacology ; Tumor Cells, Cultured</subject><ispartof>British journal of haematology, 2016-04, Vol.173 (1), p.59-69</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03</citedby><cites>FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26728969$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tucci, Marco</creatorcontrib><creatorcontrib>Stucci, Stefania</creatorcontrib><creatorcontrib>Felici, Claudia</creatorcontrib><creatorcontrib>Cafforio, Paola</creatorcontrib><creatorcontrib>Resta, Leonardo</creatorcontrib><creatorcontrib>Rossi, Roberta</creatorcontrib><creatorcontrib>Silvestris, Franco</creatorcontrib><title>Cilengitide restrains the osteoclast‐like bone resorbing activity of myeloma plasma cells</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Cilengitide (CLG) is an inhibitor of both αvβ3 and αvβ5 integrins, with a defined anti‐tumour effect in glioblastoma. Pre‐clinical studies demonstrate its ability to restrain the bone resorbing property of metastatic osteotropic tumours and we have previously shown that the disablement of αvβ3 in multiple myeloma (MM) plasma cells results in exhaustion of their in vitro osteoclast (OC)‐like activity on bone substrate. Here, we investigated the effect of CLG on this functional property of MM cells. Both αvβ3 and αvβ5 were measured on primary marrow MM cells from 19 patients, and the effect of CLG on proliferation, apoptosis and adhesion was investigated in parallel with MM cell lines and OCs from healthy donors. In addition, the effect of CLG on the capability of malignant plasma cells to produce erosive lacunae on calcium phosphate was explored in relation to the activation of intracellular kinases of molecular pathways of both integrins. Ultrastructural microscopy was used to evaluate the morphological changes in MM cells due to the effect of CLG on cell adhesion. The data from our study demonstrate that CLG restrains the bone resorbing function of MM cells by disabling their adhesion properties. Further investigations in pre‐clinical studies of osteotropic tumours are warranted.</description><subject>Apoptosis - drug effects</subject><subject>bone disease</subject><subject>Bone Resorption - metabolism</subject><subject>Bone Resorption - pathology</subject><subject>Cell Adhesion - drug effects</subject><subject>Cell Proliferation - drug effects</subject><subject>cilengitide</subject><subject>Female</subject><subject>Humans</subject><subject>Integrin alphaVbeta3 - metabolism</subject><subject>Male</subject><subject>multiple myeloma</subject><subject>Multiple Myeloma - metabolism</subject><subject>Multiple Myeloma - pathology</subject><subject>Neoplasm Proteins - metabolism</subject><subject>osteoclasts</subject><subject>Osteoclasts - metabolism</subject><subject>Osteoclasts - pathology</subject><subject>Plasma Cells - metabolism</subject><subject>Plasma Cells - pathology</subject><subject>Receptors, Vitronectin - metabolism</subject><subject>Snake Venoms - pharmacology</subject><subject>Tumor Cells, Cultured</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNkL1OwzAURi0EoqUw8AIoIwxp_RM78QgVUFAlFpgYItu1W5ckLnEKysYj8Iw8CW5T2JC4w_2Wo0_3HgBOERyiMCO5XAwR4RjvgT4ijMYYJWgf9CGEaYxgkvXAkfdLCBGBFB2CHmYpzjjjffA8toWu5raxMx3V2je1sJWPmoWOnG-0U4XwzdfHZ2FfdCRdtYVcLW01j4Rq7Jtt2siZqGx14UoRrQIfQumi8MfgwIjC65NdDsDTzfXjeBJPH27vxpfTWCWU45gqSgQlqeZcKoLDkuEZLqmAhEFIM2VMlmAulNEEZ4akwkiMoJEsSVIJyQCcd72r2r2uww95af3mAlFpt_Y5SjOKE5wy_g80ZQzzDJKAXnSoqp33tTb5qralqNscwXyjPQ_a8632wJ7tatey1LNf8sdzAEYd8B50t3835Vf3k67yG9NkjVQ</recordid><startdate>201604</startdate><enddate>201604</enddate><creator>Tucci, Marco</creator><creator>Stucci, Stefania</creator><creator>Felici, Claudia</creator><creator>Cafforio, Paola</creator><creator>Resta, Leonardo</creator><creator>Rossi, Roberta</creator><creator>Silvestris, Franco</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201604</creationdate><title>Cilengitide restrains the osteoclast‐like bone resorbing activity of myeloma plasma cells</title><author>Tucci, Marco ; Stucci, Stefania ; Felici, Claudia ; Cafforio, Paola ; Resta, Leonardo ; Rossi, Roberta ; Silvestris, Franco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Apoptosis - drug effects</topic><topic>bone disease</topic><topic>Bone Resorption - metabolism</topic><topic>Bone Resorption - pathology</topic><topic>Cell Adhesion - drug effects</topic><topic>Cell Proliferation - drug effects</topic><topic>cilengitide</topic><topic>Female</topic><topic>Humans</topic><topic>Integrin alphaVbeta3 - metabolism</topic><topic>Male</topic><topic>multiple myeloma</topic><topic>Multiple Myeloma - metabolism</topic><topic>Multiple Myeloma - pathology</topic><topic>Neoplasm Proteins - metabolism</topic><topic>osteoclasts</topic><topic>Osteoclasts - metabolism</topic><topic>Osteoclasts - pathology</topic><topic>Plasma Cells - metabolism</topic><topic>Plasma Cells - pathology</topic><topic>Receptors, Vitronectin - metabolism</topic><topic>Snake Venoms - pharmacology</topic><topic>Tumor Cells, Cultured</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tucci, Marco</creatorcontrib><creatorcontrib>Stucci, Stefania</creatorcontrib><creatorcontrib>Felici, Claudia</creatorcontrib><creatorcontrib>Cafforio, Paola</creatorcontrib><creatorcontrib>Resta, Leonardo</creatorcontrib><creatorcontrib>Rossi, Roberta</creatorcontrib><creatorcontrib>Silvestris, Franco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tucci, Marco</au><au>Stucci, Stefania</au><au>Felici, Claudia</au><au>Cafforio, Paola</au><au>Resta, Leonardo</au><au>Rossi, Roberta</au><au>Silvestris, Franco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cilengitide restrains the osteoclast‐like bone resorbing activity of myeloma plasma cells</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2016-04</date><risdate>2016</risdate><volume>173</volume><issue>1</issue><spage>59</spage><epage>69</epage><pages>59-69</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
Cilengitide (CLG) is an inhibitor of both αvβ3 and αvβ5 integrins, with a defined anti‐tumour effect in glioblastoma. Pre‐clinical studies demonstrate its ability to restrain the bone resorbing property of metastatic osteotropic tumours and we have previously shown that the disablement of αvβ3 in multiple myeloma (MM) plasma cells results in exhaustion of their in vitro osteoclast (OC)‐like activity on bone substrate. Here, we investigated the effect of CLG on this functional property of MM cells. Both αvβ3 and αvβ5 were measured on primary marrow MM cells from 19 patients, and the effect of CLG on proliferation, apoptosis and adhesion was investigated in parallel with MM cell lines and OCs from healthy donors. In addition, the effect of CLG on the capability of malignant plasma cells to produce erosive lacunae on calcium phosphate was explored in relation to the activation of intracellular kinases of molecular pathways of both integrins. Ultrastructural microscopy was used to evaluate the morphological changes in MM cells due to the effect of CLG on cell adhesion. The data from our study demonstrate that CLG restrains the bone resorbing function of MM cells by disabling their adhesion properties. Further investigations in pre‐clinical studies of osteotropic tumours are warranted.</abstract><cop>England</cop><pmid>26728969</pmid><doi>10.1111/bjh.13922</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-1048 |
ispartof | British journal of haematology, 2016-04, Vol.173 (1), p.59-69 |
issn | 0007-1048 1365-2141 |
language | eng |
recordid | cdi_proquest_miscellaneous_1785242769 |
source | Wiley-Blackwell Read & Publish Collection |
subjects | Apoptosis - drug effects bone disease Bone Resorption - metabolism Bone Resorption - pathology Cell Adhesion - drug effects Cell Proliferation - drug effects cilengitide Female Humans Integrin alphaVbeta3 - metabolism Male multiple myeloma Multiple Myeloma - metabolism Multiple Myeloma - pathology Neoplasm Proteins - metabolism osteoclasts Osteoclasts - metabolism Osteoclasts - pathology Plasma Cells - metabolism Plasma Cells - pathology Receptors, Vitronectin - metabolism Snake Venoms - pharmacology Tumor Cells, Cultured |
title | Cilengitide restrains the osteoclast‐like bone resorbing activity of myeloma plasma cells |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T00%3A35%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cilengitide%20restrains%20the%20osteoclast%E2%80%90like%20bone%20resorbing%20activity%20of%20myeloma%20plasma%20cells&rft.jtitle=British%20journal%20of%20haematology&rft.au=Tucci,%20Marco&rft.date=2016-04&rft.volume=173&rft.issue=1&rft.spage=59&rft.epage=69&rft.pages=59-69&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.13922&rft_dat=%3Cproquest_cross%3E1785242769%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4592-5c53a537e99bc329bcb1399b5a0360058cff8429acfe328f37afb210fb6447b03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1776629803&rft_id=info:pmid/26728969&rfr_iscdi=true |